Tempus will commit $42 million in payments to Recursion Pharmaceuticals, restructuring a deal that replaces potentially $84 million in discretionary fees over two years with fixed payments spanning three years. The companies simultaneously extended their data partnership, initially established in 2023, through November 2029, signaling a long-term commitment to foundation models for precision medicine.
Recursion has also granted Tempus a non-exclusive worldwide license to its proprietary RNA sequencing model, known as “TxFM.” “We are thrilled to extend our collaboration with Recursion beyond the initial committed period, demonstrating the ongoing value of this partnership,” said Ryan Fukushima, CEO, Data & Apps at Tempus.
Tempus Extends Recursion Data Partnership to November 2029
This license allows Tempus to utilize Recursion’s proprietary model for AI-driven healthcare applications, potentially accelerating the development of new precision medicine tools. The agreement signifies a deepening relationship focused on using advanced technologies to improve patient outcomes and therapeutic discovery. This recalibration suggests a longer-term, more predictable financial framework for the collaboration, prioritizing sustained investment over short-term flexibility.
This extended timeline allows for continued data integration and model refinement, essential for realizing the full potential of foundation models in precision medicine. The partnership aims to combine Tempus’s extensive multimodal data library with Recursion’s RNA sequencing expertise, ultimately seeking to personalize patient care and accelerate therapeutic development.
We are thrilled to extend our collaboration with Recursion beyond the initial committed period, demonstrating the ongoing value of this partnership.
Ryan Fukushima, CEO, Data & Apps at Tempus
See today’s quantum computing news on Quantum Zeitgeist for the latest breakthroughs in qubits, hardware, algorithms, and industry deals.
